Citations

Clear

4847 citation(s) found for "Yu, Eric".

Analysis of Abdominal Dermal‐Fat Grafting to Repair Parotidectomy Defects: An 18‐Year Cohort Study
Gruszczynski, Nelson , Anderies, Barrett J. , Dey, Jacob K. , Moore, Eric J. , Janus, Jeffrey R. , Gruszczynski, Nelson R , Dey, Jacob K , Price, Daniel L.

Mayo Clinic

The Laryngoscope | January 7, 2020 | Volume: 130 | Issue: 9 | Pages: 2144-2147

10.1002/lary.28466 | PMID 31909842 Get It

ObjectivesTo assess the outcomes of abdominal dermal‐fat grafting following superficial and total parotidectomy.MethodsA retrospective chart review of parotidectomy patients was performed. Patients were divided into four groups based on surgical extent and grafting status: superficial parotidectomy (SP), superficial parotidectomy with grafting (SPg), total parotidectomy (TP), and total parotidectomy with grafting (TPg). Complication rates and operative times were then compared between surgically matched groups (SP vs. SPg, TP vs. TPg). Complications included graft necrosis, gustatory sweating, first‐bite syndrome, infection, hematoma, sialocele, and seroma. Data was analyzed via chi‐square and two‐sample t testing, logistic regression, and one‐way analysis of variance.ResultsThe cohort consisted of 330 patients: 106 SP (32.12%), 61 SPg (18.48%), 82 TP (24.85%), and 81 TPg (24.55%). No donor site complications occurred. TPg resulted in seven graft necroses (8.64%), and 22 reported gustatory sweating (27.20% vs. 10 TP patients (12.2%), P = 0.016); SPg resulted in two necroses (3.28%). There were no other statistically significant differences in complication rates. Graft recipients receiving adjuvant radiation were more likely to develop necrosis (odds ratio [OR] 4.60, 95% confidence interval [CI], 1.16–18.27, P = .0194). Patients who developed gustatory sweating were 8.38 years younger (95% CI 2.66–14.10, P = 0.002, follow‐up time > 48 days). Grafting did not increase operative times (TP/TPg: mean = 275.91/263.65 minutes, standard error of the mean = 41.96/33.75, P = 0.822).ConclusionAn abdominal dermal‐fat graft is an excellent reconstructive choice for a parotidectomy defect and is not associated with increased complication rates or prolonged operative time.Level of Evidence4 Laryngoscope, 130:2144–2147, 2020
Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation
Inohara, Taku , Holmes, DaJuanicia N. , Pieper, Karen S. , Blanco, Rosalia , Ezekowitz, Michael D. , Kowey, Peter R. , Reiffel, James A. , Mahaffey, Kenneth W. , Singer, Daniel E. , Piccini, Jonathan P. , Steinberg, Benjamin A , Allen, Larry A. , Fonarow, Gregg C. , Gersh, Bernard J. , Hylek, Elaine M. , Naccarelli, Gerald V. , Chan, Paul Shing-fong , Freeman, James V. , Steinberg, Benjamin A. , Peterson, Eric D.

Mayo Clinic

Heart | January 7, 2020 | Volume: 106 | Issue: 5 | Pages: 358-364

10.1136/heartjnl-2019-315792 | PMID 31911503 Get It

Objective Non-vitamin K oral anticoagulants (NOACs) require dose adjustment for renal function. We sought to investigate change in renal function over time in patients with atrial fibrillation (AF) and whether those on NOACs have appropriate dose adjustments according to its decline. Methods We included patients with AF enrolled in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II registry treated with oral anticoagulation. Worsening renal function (WRF) was defined as a decrease of >20% in creatinine clearance (CrCl) from baseline. The US Food and Drug Administration (FDA)-approved package inserts were used to define the reduction criteria of NOACs dosing. Results Among 6682 patients with AF from 220 sites (median age (25th, 75th): 72.0 years (65.0, 79.0); 57.1% male; median CrCl at baseline: 80.1 mL/min (57.4, 108.5)), 1543 patients (23.1%) experienced WRF with mean decline in CrCl during 2 year follow-up of −6.63 mL/min for NOACs and −6.16 mL/min for warfarin. Among 4120 patients on NOACs, 154 (3.7%) patients had a CrCl decline sufficient to warrant FDA-recommended dose reductions. Of these, NOACs dosing was appropriately reduced in only 31 (20.1%) patients. Compared with patients with appropriately reduced NOACs, those without were more likely to experience bleeding complications (major bleeding: 1.7% vs 0%; bleeding hospitalisation: 2.6% vs 0%) at 1 year. Conclusions In the US practice, about one-fourth of patients with AF had >20% decline in CrCl over time during 2 year follow-up. As a result, about 3.7% of those treated with NOACs met guideline criteria for dose reduction, but of these, only 20.1% actually had a reduction.
Treatment of migraine in patients with CADASIL
Glover, Patrick , Brigham, Tara , Lesser, Elizabeth R. , Brott, Thomas G. , Glover, Patrick A, Goldstein, Eric D , Badi, Mohammed K. , Brigham, Tara J, Brigham, T J , Goldstein, Eric , Meschia, James F.

Mayo Clinic

Neurology Clinical Practice | January 6, 2020 | Volume: 10 | Issue: 6 | Pages: 488-496

10.1212/cpj.0000000000000769 | PMID 33520412 Get It

PSP-like syndrome after aortic surgery in adults (Mokri syndrome)
Tisel, Sarah M. , Ahlskog, J. Eric , Matsumoto, Joseph Y., Josephs, Keith A. , Duffy, Joseph R.

Mayo Clinic

Neurology Clinical Practice | January 6, 2020 | Volume: 10 | Issue: 3 | Pages: 245-254

10.1212/cpj.0000000000000708 | PMID 32642326 Get It

Levodopa-induced dyskinesia in dementia with Lewy bodies and Parkinson disease with dementia
Turcano, Pierpaolo , Stang, Cole , Bower, James H., Ahlskog, J. Eric , Savica, Rodolfo , Stang, Cole D., Boeve, Bradley F. , Mielke, Michelle M.

Mayo Clinic

Neurology Clinical Practice | January 6, 2020 | Volume: 10 | Issue: 2 | Pages: 156-161

10.1212/cpj.0000000000000703 | PMID 32309034 Get It

SPECC1L regulates palate development downstream of IRF6
Hall, Everett G. , Wenger, Luke W., Wilson, Nathan R. , Undurty-Akella, Sraavya S, Standley, Jennifer , Augustine-Akpan, Eno-Abasi, Kousa, Youssef A. , Acevedo, Diana S., Goering, Jeremy P., Pitstick, Lenore, Natsume, Nagato , Paroya, Shahnawaz, Busch, Tamara , Mori, Akihiro , Schultz‐Rogers, Laura , Klee, Eric W. , Babovic‐Vuksanovic, Dusica , Kroc, Sarah A., Eshete, Mekonen , Bjork, Bryan C. , Suzuki, Satoshi , Murray, Jeffrey C. , Schutte, Brian C. , Butali, Azeez , Saadi, Irfan , Schultz-Rogers, Laura E, Babovic-Vuksanovic, Dusica, Wilson, Nathan R, Augustine‐Akpan, Eno‐Abasi, Ito, Masaaki, Mori, Akihiro, Imura, Hideto , Adeyemo, Wasiu Lanre

Mayo Clinic

Human Molecular Genetics | January 6, 2020 | Volume: 29 | Issue: 5 | Pages: 845-858

10.1093/hmg/ddaa002 | PMID 31943082 Get It

Abstract SPECC1L mutations have been identified in patients with rare atypical orofacial clefts and with syndromic cleft lip and/or palate (CL/P). These mutations cluster in the second coiled-coil and calponin homology domains of SPECC1L and severely affect the ability of SPECC1L to associate with microtubules. We previously showed that gene-trap knockout of Specc1l in mouse results in early embryonic lethality. We now present a truncation mutant mouse allele, Specc1lΔC510, that results in perinatal lethality. Specc1lΔC510/ΔC510 homozygotes showed abnormal palate rugae but did not show cleft palate. However, when crossed with a gene-trap allele, Specc1lcGT/ΔC510 compound heterozygotes showed a palate elevation delay with incompletely penetrant cleft palate. Specc1lcGT/ΔC510 embryos exhibit transient oral epithelial adhesions at E13.5, which may delay shelf elevation. Consistent with oral adhesions, we show periderm layer abnormalities, including ectopic apical expression of adherens junction markers, similar to Irf6 hypomorphic mutants and Arhgap29 heterozygotes. Indeed, SPECC1L expression is drastically reduced in Irf6 mutant palatal shelves. Finally, we wanted to determine if SPECC1L deficiency also contributed to non-syndromic (ns) CL/P. We sequenced 62 Caucasian, 89 Filipino, 90 Ethiopian, 90 Nigerian and 95 Japanese patients with nsCL/P and identified three rare coding variants (p.Ala86Thr, p.Met91Iso and p.Arg546Gln) in six individuals. These variants reside outside of SPECC1L coiled-coil domains and result in milder functional defects than variants associated with syndromic clefting. Together, our data indicate that palate elevation is sensitive to deficiency of SPECC1L dosage and function and that SPECC1L cytoskeletal protein functions downstream of IRF6 in palatogenesis.
Fungal beta-glucan interacts with vitronectin and stimulates tumor necrosis factor alpha release from macrophages
Olson, Eric J. , Standing, Joseph E., Griego-Harper, N, Hoffman, O A, Limper, Andrew H.

Mayo Clinic

Infection and Immunity | January 6, 2020 | Volume: 64 | Issue: 9 | Pages: 3548-3554

10.1128/iai.64.9.3548-3554.1996 | PMID 8751898 Get It

beta-Glucans are polymers of D-glucose which represent major structural components of fungal cell walls. It was shown previously that fungi interact with macrophages through beta-glucan receptors, thereby inducing release of tumor necrosis factor alpha (TNF-alpha). Additional studies demonstrated that vitronectin, a host adhesive glycoprotein, binds to fungi and enhances macrophage recognition of these organisms. Since vitronectin contains a carbohydrate-binding region, we postulated that vitronectin binds fungal beta-glucans and subsequently augments macrophage TNF-alpha release in response to this fungal component. To study this, we first determined the release of TNF-alpha from alveolar macrophages stimulated with fungal beta-glucan. Maximal TNF-alpha release occurred with moderate concentrations of beta-glucan (100 to 200 micrograms/ml), whereas higher concentrations of beta-glucan (> or = 500 micrograms/ml) caused apparent suppression of the TNF-alpha activity released. This suppression of TNF-alpha activity by high concentrations of beta-glucan was mediated by the particulate beta-glucan binding soluble TNF-alpha, through the lectin-binding domain of the cytokine, rendering the TNF-alpha less available for measurement. Next, we assessed the interaction of vitronectin with beta-glucan. Binding of 125I-vitronectin to particulate fungal beta-glucan was dose dependent and specifically inhibitable by unlabeled vitronectin. Furthermore, treatment of beta-glucan with vitronectin substantially augmented macrophage TNF-alpha release in response to this fungal component. These findings demonstrate that fungal beta-glucan can directly modulate TNF-alpha release from macrophages. Further, these studies indicate that the host adhesive glycoprotein vitronectin specifically binds beta-glucan and augments macrophage cytokine release in response to this fungal element.
A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer
Zhong, Jun, Jermusyk, Ashley , Wu, Lang , Hoskins, Jason W. , Collins, Irene , Mocci, Evelina , Song, Lei , Chung, Charles C., Xiao, Wenming , Andreotti, Gabriella , Arslan, Alan A. , Babić, Ana , Berndt, Sonja, Borgida, Ayelet , Bracci, Paige M. , Brennan, Paul , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Childs, Erica J., Du, Mengmeng , Fuchs, Charles S. , Gallinger, Steven , Gaziano, J. Michael, Giovannucci, Edward L. , Goodman, Gary E. , Goodman, Phyllis J. , Haiman, Christopher, Hartge, Patricia, Hasan, Manal , Helzlsouer, Kathy J., Holly, Elizabeth A., Klein, Eric A. , Kogevinas, Manolis, Kurtz, Robert J., Ng, Kimmie , Obazee, Ofure , Oberg, Ann L. , Patel, Alpa V. , Peters, Ulrike , Porta, Miquel , Rothman, Nathaniel , Scélo, Ghislaine , Sesso, Howard D. , Sieri, Sabina , Tjønneland, Anne , Thornquist, Mark, Trichopoulou, Antonia , Visvanathan, Kala , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Yuan, Chen , Zeleniuch‐Jacquotte, Anne , Hoover, Robert N. , Brown, Kevin M. , Jacobs, Eric J. , Li, Donghui , Yu, Kai , Wolpin, Brian M. , Chatterjee, Nilanjan , Shi, Jianxin , Petersen, Gloria M. , Zhong, Jun , Arslan, Alan A , Tjønneland, Anne , Wactawski-Wende, Jean , Visvanathan, Kala , Klein, Eric A , Porta, Miquel , Zeleniuch-Jacquotte, Anne , Zhong, Jun , Yuan, Chen , Hoskins, Jason W , Zhang, Mingfeng , Zhang, Tongwu , Albanes, Demetrius , Bamlet, William R. , Freeman, Laura E. Beane , Brais, Lauren K , Canzian, Federico , Cotterchio, Michelle , Duell, Eric J. , Giles, Graham G. , Goggins, Michael , Marchand, Loı̈c Le , Malats, Núria , Männistö, Satu , Milne, Roger L. , Neale, Rachel Ε. , Orlow, Irene , Rothman, Nathaniel , Severi, Gianluca , Silverman, Debra T. , Sund, Malin , Tobias, Geoffrey S. , Van Den Eeden, Stephen K , White, Emily , Yu, Kai , Kooperberg, Charles , Risch, Harvey A. , Shu, Xiao‐Ou , Chanock, Stephen Jacob , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Smith, Jill Palmer , Kraft, Peter , Zheng, Wei , Ámundadóttir, Laufey T.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | December 31, 2019 | Volume: 112 | Issue: 10 | Pages: 1003-1012

10.1093/jnci/djz246 | PMID 31917448 Get It

Abstract Background Although 20 pancreatic cancer susceptibility loci have been identified through genome-wide association studies in individuals of European ancestry, much of its heritability remains unexplained and the genes responsible largely unknown. Methods To discover novel pancreatic cancer risk loci and possible causal genes, we performed a pancreatic cancer transcriptome-wide association study in Europeans using three approaches: FUSION, MetaXcan, and Summary-MulTiXcan. We integrated genome-wide association studies summary statistics from 9040 pancreatic cancer cases and 12 496 controls, with gene expression prediction models built using transcriptome data from histologically normal pancreatic tissue samples (NCI Laboratory of Translational Genomics [n = 95] and Genotype-Tissue Expression v7 [n = 174] datasets) and data from 48 different tissues (Genotype-Tissue Expression v7, n = 74–421 samples). Results We identified 25 genes whose genetically predicted expression was statistically significantly associated with pancreatic cancer risk (false discovery rate < .05), including 14 candidate genes at 11 novel loci (1p36.12: CELA3B; 9q31.1: SMC2, SMC2-AS1; 10q23.31: RP11-80H5.9; 12q13.13: SMUG1; 14q32.33: BTBD6; 15q23: HEXA; 15q26.1: RCCD1; 17q12: PNMT, CDK12, PGAP3; 17q22: SUPT4H1; 18q11.22: RP11-888D10.3; and 19p13.11: PGPEP1) and 11 at six known risk loci (5p15.33: TERT, CLPTM1L, ZDHHC11B; 7p14.1: INHBA; 9q34.2: ABO; 13q12.2: PDX1; 13q22.1: KLF5; and 16q23.1: WDR59, CFDP1, BCAR1, TMEM170A). The association for 12 of these genes (CELA3B, SMC2, and PNMT at novel risk loci and TERT, CLPTM1L, INHBA, ABO, PDX1, KLF5, WDR59, CFDP1, and BCAR1 at known loci) remained statistically significant after Bonferroni correction. Conclusions By integrating gene expression and genotype data, we identified novel pancreatic cancer risk loci and candidate functional genes that warrant further investigation.
Human commensal gram negative bacteria suppress systemic IL‐17 expression in AEoDQ8 transgenic mice.
Barton, Susan H., Marietta, Eric, Marshall, Behrens D, Jacobson, Melissa, Piper, Kerryl E., David, Chella S., Murray, Joseph A.

Mayo Clinic

The FASEB Journal | December 30, 2019 | Volume: 22 | Issue: S2 | Pages: 436-436

10.1096/fasebj.22.2_supplement.436 Get It

HLA‐DQ8 is associated with certain autoimmune diseases including celiac disease, juvenile diabetes mellitus, and rheumatoid arthritis. These diseases have significantly high morbidity and mortality rates and often require chronic, life‐long immunosuppressive therapy, especially in the case of rheumatoid arthritis. Recent studies have determined that commensal microorganisms from the gut flora can modulate the development of autoimmune diseases although the mechanism of action remains elusive. We examined the systemic immunological effects following oral exposure to live commensal bacteria within naive AEoDQ8 mice. Specifically, Prevotella species was isolated and cultured from the small intestine of celiac patients and administered by oral gavages every 48 hours for 2 weeks to AEo DQ8 mice. Significant decreases in serum IL‐17 expressed in pg/ml (2406 to 1662, □33%) and GM‐CSF (15.5 to 9.7, □40%) were detected in the sera of the group administered live bacteria as compared to the group administered sham gavages. The decrease in serum IL‐6, G‐CSF, MIP1a, and MIP1b levels did not reach statistical significance. Also, no difference in serum TGFbeta levels was observed between the two groups. However, FACS analysis revealed an increase in splenic CD4+CD25+FoxP3+ regulatory T‐cells in the group administered live bacteria as compared to the control group, 11.4% vs. 8.0%, respectively. These findings suggest that gram negative, commensal bacteria can suppress the expression of pro‐inflammatory IL‐17 at a systemic level.
Functional Analysis of the SIM1 Variant p.G715V in 2 Patients With Obesity
Blackburn, Patrick R. , Sullivan, Adrienne E. , Gerassimou, Alexis G , Kleinendorst, Lotte , Bersten, David C. , Cooiman, Mellody I. , Harris, Kimberly G., Wierenga, Klaas J. , Klee, Eric W. , Gerpen, Jay A. van, Ross, Owen A. , Haelst, Mieke M. van , Whitelaw, Murray L. , Caulfield, Thomas R. , Van Gerpen, Jay A, Caulfield, Thomas R , Ross, Owen A , Atwal, Paldeep S

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 24, 2019 | Volume: 105 | Issue: 1 | Pages: 355-361

10.1210/clinem/dgz192 | PMID 31872862 Get It

Abstract Context Single-minded homologue 1 (SIM1) is a transcription factor with several physiological and developmental functions. Haploinsufficiency of SIM1 is associated with early-onset obesity with or without Prader-Willi–like (PWL) features and may exhibit incomplete penetrance. Case Description Next-generation sequencing was performed for 2 male patients with obesity, including 1 man presenting with intellectual disability (ID), body mass index (BMI) of 47.4, and impulse-control disorder, and the other man with early obesity (BMI of 36); sequencing revealed a missense variant in SIM1 (c.2144G>T; p.G715V) in both individuals. Previous studies have identified several disease-associated variants that fall near the p.G715V variant within the C-terminal domain of SIM1. We examined p.G715V variant stability and activity in a doxycycline-inducible stable cell line transfected with an artificial reporter construct and either ARNT or ARNT2 as a partner protein. Conclusions Functional testing of the p.G715V variant revealed a significant reduction in SIM1-mediated transcriptional activity. We also generated the first ab initio hybrid protein model for full-length SIM1 to show the predicted spatial relationship between p.G715V and other previously described variants in this region and identified a putative mutation hotspot within the C-terminus. Significant clinical heterogeneity has been observed in patients with SIM1 variants, particularly with regards to the PWL phenotype. In the patient with ID, a second variant of uncertain significance in CHD2 was identified that may contribute to his ID and behavioral disturbances, emphasizing the role of additional genetic modifiers.